The ASO for myotonic dystrophy type 1 was well tolerated and improved splicing and function in a study presented at ASGCT.

Data from the EMBARK trial suggest patients may have functional improvements taking the gene therapy between 8 and 9 years old.

The analysis by Ontada tracked testing rates withing the US Oncology Network for PD-L1, FGFR2/3, and HER2 biomarkers over 10 years.

In a Phase Ia trial in ovarian cancer, a strong neutralizing antibody response correlated with better disease control and ...